Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s525481 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Teng-Fei Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine Ward 2, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Indoles, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
This study aims to evaluate the efficacy and safety of anlotinib combined with immune checkpoint inhibitors (ICIs) in patients with previously immunotherapy-treated extensive-stage small cell lung cancer (ES-SCLC).
Methods
This retrospective study screened ES-SCLC patients who experienced failure after prior ICIs-based treatment and received anlotinib combined with ICIs therapy clinically. Anlotinib was administered at a standard dosage, ICIs regimens included PD-1 inhibitors (Tislelizumab, 200 mg; serplulimab, 4.5 mg/kg) and PD-L1 inhibitors. Efficacy and safety data during treatment were retrospectively collected, and patients were followed up regularly to obtain long-term survival data. Subgroup analysis was conducted to identify the differences in treatment outcomes in various baseline characteristics.
Results
Of the 68 ES-SCLC patients included, no complete response, 22 patients achieved partial response, 28 had stable disease, 14 experienced disease progression and 4 patients were not available for efficacy. Objective response rate (ORR) was 32.4% (95% CI: 21.5-44.8%), and disease control rate (DCR) was 73.5% (95% CI: 61.4-83.5%). The median progression-free survival (PFS) was 5.6 months (95% CI: 3.87-7.33), the median duration of response (DoR) was 6.8 months (95% CI: 0.80-12.83). At the data cutoff date, the median follow-up duration was 12.5 months (range: 1.1-31.5 months), yielding a median overall survival (OS) of 13.2 months (95% CI: 7.09-19.31). Subgroup analysis highlighted that patients who were previously intolerant to immunotherapy had a longer OS (median OS: 15.5 vs 10.9 months, P = 0.031). Safety analysis showed that 61 patients (89.7%) experienced treatment-related adverse events (TRAEs) of varying severity with 37 patients (54.4%) developing grade 3 or higher. The most common TRAEs included fatigue, nausea and vomiting, hypertension, hematologic toxicity, and liver function abnormalities.
Conclusion
Anlotinib combined with ICIs demonstrated that immunotherapy rechallenge in previously ICIs-treated ES-SCLC was feasible and of clinical significance preliminarily. However, larger-scale clinical studies were required to validate these findings subsequently.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine Ward 2, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
- Department of Respiratory Medicine Ward 1, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China.
Zitieren
APA
Chen, T. F., Li, Z. J., Zhao, H. S., & Yang, R. (2025). Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s525481
Vancouver
Chen TF, Li ZJ, Zhao HS, Yang R. Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s525481
BibTeX
@article{Chen2025,
author = {Chen, Teng-Fei and Li, Zhan-Jiang and Zhao, Hua-Si and Yang, Rui},
title = {Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s525481}
}
EUVIMED